Search Results - "Bissonnette R"

Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.

Authors: Bissonnette, R. Saint‐Cyr Proulx, E. Jack, C. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jun2023, Vol. 37 Issue 6, p1168-1174. 7p.

Estimands for atopic dermatitis clinical trials: Expert opinion on the importance of intercurrent events.

Authors: Bissonnette, R. Eichenfield, L. F. Simpson, E. et al.

Source: Journal of the European Academy of Dermatology & Venereology. May2023, Vol. 37 Issue 5, p976-983. 8p.

Changes in serum free testosterone, sleep patterns, and 5-alpha-reductase type I activity influence changes in sebum excretion in female subjects.

Authors: Bissonnette, R. Risch, J. E. McElwee, K. J. et al.

Source: Skin Research & Technology. Feb2015, Vol. 21 Issue 1, p47-53. 7p.

Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris.

Authors: Bissonnette, R. Bolduc, C. Seité, S. et al.

Source: Journal of Cosmetic Dermatology. Mar2009, Vol. 8 Issue 1, p19-23. 5p. 5 Graphs.

XP-828L in the treatment of mild-to-moderate psoriasis: a randomized, double-blind, placebo-controlled study.

Authors: Poulin Y Bissonnette R Juneau C et al.

Source: Alternative Medicine Review. Dec2007, Vol. 12 Issue 4, p352-359. 8p.

URL: 28122751

Incidence of cardiovascular events among tildrakizumab‐treated patients with moderate‐to‐severe plaque psoriasis: pooled data from three large randomised clinical trials.

Authors: Bissonnette, R. Fernández‐Peñas, P. Puig, L. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jan2020, Vol. 34 Issue 1, pe21-e24. 4p.

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study

Authors: Bissonnette, R. Maari, C. Forman, S. et al.

Source: British Journal of Dermatology. Oct2019, Vol. 181 Issue 4, p733-742. 10p.

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement.

Authors: Leshem, Y.A. Bissonnette, R. Paul, C. et al.

Source: Journal of the European Academy of Dermatology & Venereology. May2019, Vol. 33 Issue 5, p807-815. 9p.

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).

Authors: Bissonnette, R. Luger, T. Thaçi, D. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Sep2018, Vol. 32 Issue 9, p1507-1514. 8p.

Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: results from a double‐blind, placebo‐controlled, randomized study.

Authors: Bissonnette, R. Haydey, R. Rosoph, L. A. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Mar2018, Vol. 32 Issue 3, p403-410. 8p.

A phase 2a randomized controlled study to evaluate the pharmacokinetic, safety, tolerability and clinical effect of topically applied Umeclidinium in subjects with primary axillary hyperhidrosis.

Authors: Nasir, A. Bissonnette, R. Maari, C. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Jan2018, Vol. 32 Issue 1, p145-151. 7p.

Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.

Authors: Bissonnette, R. Luger, T. Thaçi, D. et al.

Source: British Journal of Dermatology. Oct2017, Vol. 177 Issue 4, p1033-1042. 10p.

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

Authors: Bissonnette, R. Papp, K.A. Poulin, Y. et al.

Source: British Journal of Dermatology. Nov2016, Vol. 175 Issue 5, p902-911. 10p.

Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.

Authors: Bissonnette, R. Maari, C. Barber, K. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Aug2015, Vol. 29 Issue 8, p1576-1581. 6p.

This result is not displayed to guests.
Login for full access.

Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.

Authors: Bissonnette, R. Iversen, L. Sofen, H. et al.

Source: British Journal of Dermatology. May2015, Vol. 172 Issue 5, p1395-1406. 12p.

Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar ( PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.

Authors: Bissonnette, R. Nigen, S. Langley, R.G. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Oct2014, Vol. 28 Issue 10, p1298-1305. 8p.

Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy.

Authors: Basset ‐ Seguin, N. Bissonnette, R. Girard, C. et al.

Source: Journal of the European Academy of Dermatology & Venereology. May2014, Vol. 28 Issue 5, p626-632. 7p.

Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial.

Authors: Bissonnette, R. Bolduc, C. Maari, C. et al.

Source: Journal of the European Academy of Dermatology & Venereology. Dec2012, Vol. 26 Issue 12, p1516-1521. 6p.

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial.

Authors: Bissonnette, R. Poulin, Y. Zhou, Y. et al.

Source: British Journal of Dermatology. Apr2012, Vol. 166 Issue 4, p853-860. 8p.